14 - 19
Apr 2023
AACR 2023
Annual meeting highlighting cancer research from institutions worldwide.
Five-year Efficacy and Safety of Tafasitamab in Patients with Relapsed or Refractory DLBCL: Final Results from the Phase II L-MIND Study
Preclinical Study of CD19 Detection Methods Using Monoclonal Antibodies post Tafasitamab Treatment
MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.
You are now leaving the MorphoSys.com website. This link will take you to a different website. You are solely responsible for your interactions with that website.
Do you wish to proceed ?
MorphoSys is providing the data presented at medical congresses as part of scientific exchange. The scientific information may include data/information on investigational use(s) of compounds/drugs of which the efficacy and safety have not yet been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of MorphoSys’ products. Copies of congress presentations may not be reproduced without written permission from the congress and the authors.